Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2021

01-07-2021 | Pneumococcus | Original Article

Effect of childhood pneumococcal vaccination and beta-lactam antibiotic use on the incidence of invasive pneumococcal disease in the adult population

Authors: Abelardo Fernández Chávez, Luis García Comas, Juan Carlos Sanz Moreno, Rafael Cantón Moreno, Octavio Corral Pazos de Provens, Jesús María Aranaz Andrés

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2021

Login to get access

Abstract

Describe the incidence of invasive pneumococcal disease (IPD) in serotypes with reduced antibiotic sensitivity to penicillin (RAS-Pen) in adults over 59 years of age and its association with childhood anti-pneumococcal vaccination coverage (CVC) and community consumption of beta-lactam. We selected IPD cases in adults over 59 years of age reported in the Community of Madrid between 2007 and 2016. We estimated the incidence of cases caused by serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13), those not included (non-PCV13) and the six serotypes additional to the 7-valent (PCV13-no7). We compared the incidences of serotypes from the pre-vaccine period (2007–2009) and the vaccine period (2011–2016) by analysing the incidence trend (JointPoint Trend Analysis) and its association with the CVC and community consumption of beta-lactam (Poisson model). We identified 1936 cases of IPD, 29.2% (n = 565) in serotypes with RAS-Pen. The incidence decreased for PCV13 cases (annual percentage of change, APC: -12.2, p < 0.05) and increased for non-PCV13 (APC: 15.4, p < 0.05). The incidence of IPD due to non-PCV13 was associated with community beta-lactam consumption (IRR 1.156; CI95% 1.025–1.304) and that of cases of PCV13-no7 with CVC (IRR 0.574; 95% CI95% 0.413–0.797). The non-PCV13 strains that increased the most at the end of the period were 6C, 11A and 15A. The incidence of IPD due to PCV13 with RAS-Pen at > 59 years was decreasing and was associated with CVC. The incidence of cases due to non-PCV13 was increasing and was associated with community consumption of beta-lactam.
Literature
1.
go back to reference Liñares J, Ardanuy C, Pallares R, Fenoll A (2010) Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 16(5):402–410 Liñares J, Ardanuy C, Pallares R, Fenoll A (2010) Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 16(5):402–410
2.
go back to reference Lynch JP, Zhanel GG (2010) Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 16(3):217–225PubMed Lynch JP, Zhanel GG (2010) Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 16(3):217–225PubMed
3.
go back to reference 23-valent pneumococcal polysaccharide vaccine (2008) WHO position paper. Releve Epidemiol Hebd. 83(42):373–384 23-valent pneumococcal polysaccharide vaccine (2008) WHO position paper. Releve Epidemiol Hebd. 83(42):373–384
6.
go back to reference Hays C, Vermee Q, Agathine A, Dupuis A, Varon E, Poyart C et al (2017) Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 36(5):831–838CrossRef Hays C, Vermee Q, Agathine A, Dupuis A, Varon E, Poyart C et al (2017) Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 36(5):831–838CrossRef
7.
go back to reference Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S et al (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 372(12):1114–1125CrossRef Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S et al (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 372(12):1114–1125CrossRef
8.
go back to reference van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 15:207CrossRef van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 15:207CrossRef
9.
go back to reference Tin Tin Htar M, Christopoulou D, Schmitt H-J (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15:419CrossRef Tin Tin Htar M, Christopoulou D, Schmitt H-J (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15:419CrossRef
10.
go back to reference Moreno-Pérez D, Álvarez García FJ, Arístegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM et al (2012) Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2012. An Pediatría 76(1):42.e1–42.e23CrossRef Moreno-Pérez D, Álvarez García FJ, Arístegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM et al (2012) Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2012. An Pediatría 76(1):42.e1–42.e23CrossRef
11.
go back to reference Hicks LA, Chien Y-W, Taylor TH, Haber M, Klugman KP, on behalf of the Active Bacterial Core Surveillance (ABCs) Team (2011) Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis. 53(7):631–639CrossRef Hicks LA, Chien Y-W, Taylor TH, Haber M, Klugman KP, on behalf of the Active Bacterial Core Surveillance (ABCs) Team (2011) Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis. 53(7):631–639CrossRef
12.
go back to reference Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Ré R, Baquero F (2000) Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979–1997). J Antimicrob Chemother. 46(5):767–773CrossRef Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Ré R, Baquero F (2000) Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979–1997). J Antimicrob Chemother. 46(5):767–773CrossRef
13.
go back to reference Goossens H, Ferech M, Vander Stichele R, Elseviers M (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet. 365(9459):579–587CrossRef Goossens H, Ferech M, Vander Stichele R, Elseviers M (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet. 365(9459):579–587CrossRef
14.
go back to reference Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV (2009) Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin Infect Dis. 48(3):e23–e33CrossRef Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV (2009) Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin Infect Dis. 48(3):e23–e33CrossRef
17.
go back to reference Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM et al (2015) Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 15(3):301–309CrossRef Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM et al (2015) Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 15(3):301–309CrossRef
18.
go back to reference Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M et al (2014) Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 14(9):839–846CrossRef Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M et al (2014) Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 14(9):839–846CrossRef
19.
go back to reference Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M et al (2016) Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine. 34(38):4565–4571CrossRef Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M et al (2016) Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine. 34(38):4565–4571CrossRef
20.
go back to reference Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R (2008) Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 46(2):174–182CrossRef Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R (2008) Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 46(2):174–182CrossRef
21.
go back to reference Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI (2014) Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 33(5):504–510CrossRef Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI (2014) Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 33(5):504–510CrossRef
23.
go back to reference Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH et al (2016) Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 4(5):399–406CrossRef Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH et al (2016) Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 4(5):399–406CrossRef
24.
go back to reference Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV (2014) Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. AAC.03344-14 Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV (2014) Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. AAC.03344-14
25.
go back to reference Aguinagalde L, Corsini B, Domenech A, Domenech M, Cámara J, Ardanuy C et al (2015) Emergence of amoxicillin-resistant variants of Spain9 V-ST156 pneumococci expressing serotype 11A correlates with their ability to evade the host immune response. PloS One. 10(9):e0137565CrossRef Aguinagalde L, Corsini B, Domenech A, Domenech M, Cámara J, Ardanuy C et al (2015) Emergence of amoxicillin-resistant variants of Spain9 V-ST156 pneumococci expressing serotype 11A correlates with their ability to evade the host immune response. PloS One. 10(9):e0137565CrossRef
26.
go back to reference Makwana A, Ladhani SN, Kapatai G, Campion E, Fry NK, Sheppard C (2018) Rapid spread of pneumococcal nonvaccine serotype 7C previously associated with vaccine serotype 19F, England and Wales. Emerg Infect Dis. 24(10):1919–1922CrossRef Makwana A, Ladhani SN, Kapatai G, Campion E, Fry NK, Sheppard C (2018) Rapid spread of pneumococcal nonvaccine serotype 7C previously associated with vaccine serotype 19F, England and Wales. Emerg Infect Dis. 24(10):1919–1922CrossRef
27.
go back to reference Mäkelä PH, Käyhty H (2002) Evolution of conjugate vaccines. Expert Rev Vaccines. 1(3):399–410CrossRef Mäkelä PH, Käyhty H (2002) Evolution of conjugate vaccines. Expert Rev Vaccines. 1(3):399–410CrossRef
28.
go back to reference Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 10(3):307–322CrossRef Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 10(3):307–322CrossRef
29.
go back to reference Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AWJ, Tikoduadua L et al (2010) Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 28(19):3341–3349CrossRef Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AWJ, Tikoduadua L et al (2010) Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 28(19):3341–3349CrossRef
30.
go back to reference Rodríguez MAG, González AV, Gavín MAO, Martínez FM, Marín NG, Blázquez BR et al (2011) Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine. 29(34):5740–5746CrossRef Rodríguez MAG, González AV, Gavín MAO, Martínez FM, Marín NG, Blázquez BR et al (2011) Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine. 29(34):5740–5746CrossRef
31.
go back to reference Moraga-Llop FA (2009) Pneumococcal disease and emergence of serotypes in the vaccine era. Transient trends and serotype replacement? Enferm Infecc Microbiol Clin. 27(1):1–4CrossRef Moraga-Llop FA (2009) Pneumococcal disease and emergence of serotypes in the vaccine era. Transient trends and serotype replacement? Enferm Infecc Microbiol Clin. 27(1):1–4CrossRef
Metadata
Title
Effect of childhood pneumococcal vaccination and beta-lactam antibiotic use on the incidence of invasive pneumococcal disease in the adult population
Authors
Abelardo Fernández Chávez
Luis García Comas
Juan Carlos Sanz Moreno
Rafael Cantón Moreno
Octavio Corral Pazos de Provens
Jesús María Aranaz Andrés
Publication date
01-07-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-021-04196-4

Other articles of this Issue 7/2021

European Journal of Clinical Microbiology & Infectious Diseases 7/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.